Shares of Cosmo Pharmaceuticals (OTCPK:CMOPF) soared as much as 24% in Zurich—the biggest jump since 2008—after the company said that its experimental male hair loss treatment met key endpoints in two ...
Cosmo Pharmaceuticals has revealed topline results from two phase 3 trials which indicate that its topical cream clascoterone could become a game-changing treatment for male-pattern hair loss. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results